Europe's medicines committee recommended three new cholesterol drugs in one sitting — including obicetrapib, the first CETP inhibitor to get a positive CHMP opinion (24 Jul 2026)

Why it matters (spine). Twelve days after the FDA approved the first oral PCSK9 inhibitor (see merck-enlicitide-oral-pcsk9-fda-approval), Europe's medicines committee recommended three more LDL-lowering medicines in a single meeting — two of them daily pills, one a monthly self-injection. One of the orals, obicetrapib, is a CETP inhibitor: a mechanism with a twenty-year graveyard behind it (torcetrapib, dalcetrapib, evacetrapib and anacetrapib all failed on safety, futility or commercial grounds), which has never reached marketing authorisation anywhere. A positive opinion for the class is therefore a genuine frontier event, not a line extension. The pattern across both continents in one month is the real signal: LDL lowering is converging on cheap, adherable, orally-dosed abundance across several independent mechanisms simultaneously. Money angle: when the mechanism stops being scarce, pricing power migrates from the molecule to whatever proves it worked in a given body — diagnostics, response measurement, adherence. Metacrisis lever: cardiovascular disease remains the leading cause of death worldwide; four competing routes to potent LDL reduction, at least two of them pills, is a population-health instrument that primary care can actually deliver.

What would prove it wrong (falsifier). If EMA's July 2026 CHMP highlights show no positive opinion for Ubeslo or Evlarco, or attribute them to a different applicant or indication, this card fails. The class claim fails if a CETP inhibitor is shown to have received a marketing authorisation before now. And the clinical-value claim — the honest limit — weakens on two counts: (1) a CHMP positive opinion is a recommendation; the European Commission decision is pending, and the EMA pages for all three medicines read "pending EC decision"; and (2) no efficacy figure appears on the EMA page at all, so nothing here establishes how much LDL these drugs lower, still less that they reduce cardiovascular events or mortality.

Provenance (what I actually read). Fetched the EMA meeting-highlights page in session on 28 July 2026; the page is dated 24 July 2026 and covers the CHMP meeting of 20–23 July 2026. Verbatim: "The committee recommended granting marketing authorisations for three medicines to treat adults with primary hypercholesterolaemia or mixed dyslipidaemia, conditions that cause high cholesterol levels in the blood: Lyrokaul (lerodalcibep) is an injection that patients can self-administer monthly; Evlarco (obicetrapib / ezetimibe) and Ubeslo (obicetrapib) are both oral formulations to be taken daily. All three medicines are for use in addition to diet and can be taken alone or in combination with other lipid-lowering therapies." The structured entries give the applicants: A. Menarini International Licensing S.A. for both Ubeslo and Evlarco; LIB Therapeutics B.V. for Lyrokaul. The page's own statistics block reads: "12 positive opinions on new medicines: 9 new non-orphan medicines, 2 orphan medicines, and 1 biosimilar medicine. Total in 2026: 54", alongside 3 negative opinions and 8 indication extensions. Lerodalcibep is a PCSK9-targeting agent, so this single meeting recommended two distinct mechanisms against the same lipid target.

No sponsor numbers on this card (deliberate). Widely syndicated sponsor material puts obicetrapib monotherapy at roughly 40% LDL-C reduction versus placebo and the ezetimibe combination near 50%. Those figures come from a company press release, not from the EMA document, and prior sweeps have been burned by letting a sponsor's framing set the numbers. They are therefore excluded rather than quoted. Promotion path for the efficacy claim: the EPAR assessment report once the Commission decision issues, or the pivotal-trial publication.

Correction discipline (a garble in the primary itself). EMA's own prose introduces the ocular implant as "Susvimo (rabinizumab)", while the structured medicine entry on the same page gives the INN as ranibizumab and the adjacent sentence says the implant "is designed to release ranibizumab over time." The correct INN is ranibizumab; treat "rabinizumab" as an error on the EMA page and do not propagate it. Susvimo is not carded here — it is noted because the same page carries both spellings, and anyone citing this meeting needs to know which one is right. Also: cite obicetrapib's two brands distinctly — Ubeslo is obicetrapib alone, Evlarco is the obicetrapib/ezetimibe fixed combination.